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Abstract
The intracellular domains of the membrane-anchoring regions of some precursors of epidermal growth factor (EGF)
family members have intrinsic biologic activities. We have determined the role of the human proEGF cytoplasmic
domain (proEGFcyt) as part of the proEGF transmembrane–anchored region (proEGFctF) in the regulation of motility
and elastinolytic invasion in human thyroid cancer cells. We found proEGFctF to act as a negative regulator of motil-
ity and elastin matrix penetration and the presence of proEGFcyt or proEGF22.23 resulted in a similar reduction in
motility and elastinolytic migration. This activity was counteracted by EGF-induced activation of EGF receptor signal-
ing. Decreased elastinolytic migratory activity in the presence of proEGFctF and proEGFcyt/proEGF22.23 coincided
with decreased secretion of elastinolytic procathepsin L. The presence of proEGFctF and proEGFcyt/proEGF22.23
coincided with the specific transcriptional up-regulation of t-SNARE member SNAP25. Treatment with siRNA-
SNAP25 resulted inmotility and elastinmigration being restored to normal levels. Epidermal growth factor treatment
down-regulated SNAP25 protein by activating EGF receptor–mediated proteasomal degradation of SNAP25. These
data provide first evidence for an important function of the cytoplasmic domain of the human proEGF transmem-
brane region as a novel suppressor of motility and cathepsin L–mediated elastinolytic invasion in human thyroid car-
cinoma cells and suggest important clinical implications for EGF-expressing tumors.
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Introduction
The human membrane–anchored epidermal growth factor (EGF)
precursor (proEGF) is the founder and largest member (1207 amino
acid [aa]) [1] of the EGF-like growth factor family, which also in-
cludes heparin binding–EGF (HB-EGF), transforming growth fac-
tor alpha (TGFα), β-cellulin, neuregulins 1 to 4, epiregulin, epigen,
cripto, and amphiregulin. With the exception of cripto, EGF-like li-
gands bind to and activate membrane-bound EGF receptors ErbB1,
3, and 4 and have important roles in growth and differentiation [2].
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Enhanced tumor aggressiveness and shorter survival periods are
positively correlated with the presence of EGF-like ligands and ErbB
receptors [3]. Cellular localization and proteolytic processing of
membrane-anchored EGF-like precursors through members of the
ADAM family of sheddases is controlled by their membrane-anchoring
and cytoplasmic domain [4,5] and display tissue and cell type–specific
pattern [6–9].
Increasing evidence suggests important functional roles for the
transmembrane region and particularly the cytoplasmic domain of
EGF receptor (EGFR) ligands [4,5]. The proTGF alpha cytoplasmic
domain (proTGFα-cyt) was first described to interact with a kinase
complex [10] and was later confirmed to act as a binding partner for
a number of proteins involved in the maturation and intracellular
trafficking of membrane proteins. These include syntenin/mda-9/
TACIP18 (proTGFα-cyt domain-interacting protein 18) [11], Golgi
reassembly stacking protein of 55 kDa [12] and membrane-associated
guanylate kinase inverted-3 [13]. Naked2, the mammalian homolog
of Drosophila Naked Cuticle binds proTGFα-cyt and facilitates
basolateral sorting of this precursor in MDCK [14]. ProARcyt was
also shown to contain residues important for basolateral sorting in-
formation [15–17]. The function of the EGFR ligand cytoplasmic
domain is not restricted to the maturation and subcellular targeting
of the precursor but may be of clinical relevance. The nuclear local-
ization of the cytoplasmic domain of proHB-EGF (proHB-EGFcyt)
is linked to aggressive transitional cell carcinoma [18]. Among the
interaction partners of proHB-EGFcyt is the survival-promoting co-
chaperone protein Bag-1 which increases HB-EGF secretion [19]. On
shedding, proHB-EGFcyt translocates to the nucleus, binds to the
inner nuclear membrane [20], and interacts with the cyclin A transcrip-
tional repressor promyelocytic leukemia zinc finger protein and its
heterodimerization partner B-cell lymphoma 6 (Bcl6) to induce
S-phase entry [21,22]. Moreover, phosphorylation has recently been
suggested as a novel way to modulate HB-EGFcyt and TGFα-cyt
functions [23]. On binding to its ErbB receptor, neuregulin 1 (NRG1)
cytoplasmic domain (proNRG1cyt) is released into the cytosol and its
association with LIM-kinase 1 has been implicated in visual-spatial
cognition [24,25]. Soluble NRG1cyt is also a nuclear transcriptional
suppressor for several regulators of apoptosis [24] and enhances the
transcriptional activity of the promoter for postsynaptic density pro-
tein 95 (PSD-95) by binding to the zinc-finger transcription factor
Eos [26]. Finally, we identified human proEGFcyt as a novel modu-
lator of microtubule dynamics and microtubule-associated protein
(MAP) 1 and MAP2 production in human thyroid carcinoma [27].
Here, we describe a unique suppressive role of the proEGFcyt as
part of the membrane-anchored region of human proEGF in the
motility and invasiveness of thyroid cancer cells which involves the
SNAP25-mediated suppression of exocytosis of cathepsin L. These
findings may be of relevance in human thyroid cancer and have im-
portant implications for other types of proEGF-expressing cancers.
Materials and Methods
Cell Culture
Human thyroid follicular carcinoma cell lines FTC-133 and FTC-
236 were propagated in HAM’s F12 medium and 10% fetal bovine
serum (PAA Laboratories GmbH, Pasching, Austria), and the undif-
ferentiated anaplastic human thyroid carcinoma cell line UTC-8305
was grown in RPMI medium plus 20% fetal bovine serum. Stable
transfectants of FTC-133 were described previously [27]. Transient
transfections of FTC-236 and UTC-8305 were done with 1 μg of
the constructs using Lipofectamine (Life Technologies, Burlington,
Canada). Transfection efficiency was assessed by an EGFP construct
after 24 hours and calculated to be more than 70% for UTC-8305
and 50% to 60% for FTC-236. Protein lysates were harvested
24 hours after transfection for Western blot.
Mouse Model of Follicular Thyroid Carcinoma
The TRβ PV/PV mouse model of follicular thyroid carcinoma (FTC)
with a dominant-negative thyroid receptor β1mutant PV has been de-
scribed previously [28–30]. Independent of their sex, TRβ PV/PV
homozygotes develop metastasizing FTC in more than 80% of ani-
mals at 6 months [30]. Thyroid tissues were collected at 2.90, 7.73,
and 11.93 months of age, fixed in paraformaldehyde, and paraffin-
embedded for immunohistochemistry.
RNA Silencing
ProEGFcyt and -proEGF22.23 transfectants of FTC-133 at 60%
confluence were transfected with 50 nM siRNA-SNAP25 (5′GGG-
TAACAAATGATGCCCG3′; Ambion, Austin, TX) or a nonsilencing,
randomized sequence not matching any known human gene (5′AATT-
CTCCGAACGTGTCACGT3′) as a control using Lipofectamine 2000
(Life Technologies). After 48 hours, SNAP25 gene expression and
SNAP25 protein levels were assessed by reverse transcription–polymerase
chain reaction (RT-PCR) and Western blot analysis, respectively. For
siRNA experiments on filters, 20 nM of each siRNA SNAP 25 and
nonsilencing siRNA were transfected using the Effectin kit (Qiagen,
Ontario, Canada).
RNA processing and RT-PCR
Total RNA of all transfectants was isolated with Trizol reagent
(Life Technologies), and RNA amounts were determined by spectro-
photometry. Total RNA (1 μg) was used for first-strand cDNA syn-
thesis using the Superscript reverse transcriptase kit and 500 ng/ml
of oligo d(T) primer (both Life Technologies). For RT-PCR, 1 μl
cDNA and 25 pM each of specific forward and reverse primers
were used for SNAP25A+B, SNAP23, and synaptobrevin/VAMP2
(Table 1). The PCR cycle profile consisted of an initial denaturation
at 95°C for 15 minutes followed by 40 cycles of denaturation at 95°C
for 1 minute, annealing at 60°C for 1 minute, and elongation at 72°
for 2 minutes. A negative control devoid of cDNA template was in-
cluded. Single-PCR products were separated in a 2% agarose gel in
TAE buffer (EMD, San Diego, CA) and visualized by ethidium bro-
mide staining.
ProEGFcyt Antiserum
A polyclonal antiserum against human proEGFcyt was generated by
immunizing rabbits with a 15-mer palmitylated peptide, purity of >90%,
Table 1. List of Primers Used for RT-PCR.
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derived from a proEGFcyt peptide region encoded by exon 22 (EMC
Microcollections, Tuebingen, Germany). Rabbits were immunized
subcutaneously with 100 μg of peptide in 400 μl of phosphate-
buffered saline (PBS; Sigma, St. Louis, MO) plus 600 μl of complete
Freund’s adjuvant and subsequently boosted monthly for seven con-
secutive months by intramuscular injection of 100 μg of peptide in
400 μl of PBS and 600 μl of incomplete Freund’s adjuvant.
GST-proEGFcyt Fusion Protein
ProEGFcyt was PCR amplified [27] and the purified and se-
quenced amplicon was cloned into the EcoRI/NotI sites of pGEX-
5X-1 (Amersham Biosciences, Piscataway, NJ) and transformed into
Escherichia coli, strain Rosetta 2 (Novagen, EMD Biosciences, Darm-
stadt, Germany). Cells grown to mid log phase (OD600 nm = 0.5-0.7)
were induced with 0.1 mM isopropyl-β-D-thiogalactopyranoside
(Novagen, EMD Biosciences, Darmstadt, Germany) for 2 hours at
room temperature. Total cell protein was extracted from induced
and noninduced cultures. Protein expression was verified by electro-
phoresis of the total cell protein extracts on a 12% SDS-PAGE gel
followed by Coomassie staining of the gel. Frozen pellets obtained by
centrifugation of 10-ml aliquots of induced GST-proEGFcyt con-
taining Rosetta 2 cultures were resuspended in 600 μl of BugBuster
Protein Extraction Reagent (Novagen) supplemented with 12 μl of
lysozyme solution of 10 mg/ml (Sigma), 12 U of DNAase (Qiagen),
and 2 μl of protease inhibitor cocktail (Sigma) and were incubated
for 10 to 15 minutes at room temperature with gentle shaking. The
suspension was then centrifuged for 5 minutes at 17,900g. The GST-
proEGFcyt fusion protein was purified from the clear supernatant
using the MicroSpin GST Purification Module (Amersham Bio-
sciences, Piscataway, NJ) according to the manufacturer’s instructions.
The protein was eluted twice, each by incubating the column for 5 to
10 minutes with 100 μl of glutathione elution buffer. Pooled eluates
were run on a 12% SDS-PAGE gel and tested for GST-EGFcyt by
Western blot using an anti-GST antiserum (Amersham Biosciences,
Piscataway, NJ).
Western Blot Analysis and Inhibition Assay
Transfectants (8.5 × 104 cells per six-well plate) were seeded for
24 hours in serum-free medium plus/minus treatment with EGF
(10 ng/ml; Life Technologies), EGFR inhibitor AG1478 (10 μg/ml;
Sigma), and MG132 or lactacystine (both 10 μM; Sigma). For
Western blot, a monoclonal antibody (mAb) directed against β-actin
(1:20,000; Sigma) was used to assess equal loading of proteins. Se-
creted proteins were recovered from supernatants by centrifuging at
10,000g for 15 minutes at 4°C; these were then frozen at −80°C,
lyophilized, and resuspended in 1/20th of the original volume with
distilled water. Bradford assay (Biorad, Montreal, Canada) was used
to determine protein concentrations of supernatants. Equal amounts
of supernatant proteins (2 mg/ml) were separated by SDS-PAGE
and blotted onto Hybond nitrocellulose membranes (Amersham,
Braunschweig, Germany). Nonspecific binding was saturated at
room temperature for 1 hour in blocking buffer containing PBS/
0.01% Tween 20 (PBST) plus 3% skimmed milk.
For the detection of cath-L forms, membranes were incubated over-
night at 4°C with a mAbs specific for procath-L (2D4 at 1:500) and
a mAb recognizing all three cath-L forms (33/1 at 1:500) [31], re-
spectively. Other mAbs used were against human SNAP25 (1:400;
Cedarlane, Pickering, Ontario, Canada) and anti–EGFR-Tyr 992
(1:1000; Cell Signaling Technology). Human syntaxin1Awas detected
using a rabbit polyclonal antiserum (1:500; Cedarlane).
Characterization of the polyclonal antiserum against human
proEGFcyt (1:1500) was performed with protein extracts of FTC-
133-proEGFcyt and mock-stable transfectants (each at 1 × 106 cells
per milliliter) under similar conditions as described above. Anti-Xpress
antiserum (1:2000; Invitrogen, Carlsbad, CA) was used to detect
the Xpress–tagged recombinant proEGFcyt present in FTC-133-
proEGFcyt transfectants to confirm the specificity of the new anti-
proEGFcyt serum.
A rabbit polyclonal antiserum against human EGF (Z-12; Santa Cruz
Biotechnology, Santa Cruz, CA) was used at 1:200 to confirm the pres-
ence of EGFctF in stable transfectants. All antibodies were diluted in
blocking buffer and membranes were incubated overnight at 4°C. After
incubation with a horseradish peroxidase-conjugated goat antimouse Ig
(Dianova, Hamburg, Germany; 1:20,000) or a horseradish peroxidase–
conjugated goat antirabbit Ig (New England Biolabs, Pickering, Ontario,
Canada; 1:4000) for 2 hours at room temperature, specific immunore-
active bands were detected with an ECL-kit (Amersham, Braunschweig,
Germany).
For inhibition assays, the polyclonal antiserum against proEGF cyt
(1:1000) was incubated with the GST-proEGFcyt fusion protein
(8 μg/ml) in 5% powder milk blocking buffer for 4 hours at 4°C
before Western blot analyses. Rabbit nonimmune serum was used
as a control.
Cell Motility and Elastin Migration Assays
Motility and migration assays were performed on transwell poly-
ethylene membrane filters of 8-μm pore size (Greiner Bio-one,
Frickenhausen, Germany) under serum-free conditions as described
previously [32]. For 24- (FTC-133) and 48-hour (FTC-133, FTC-
236, and UTC-8305) migration assays, 1 × 104 and 1 × 103 cells,
respectively, were plated onto filters that had been coated with 40 μl
of elastin (50 μg/ml; Sigma). For some experiments, cells were treated
for 24 hours with EGF (10 ng/ml), specific EGFR inhibitor AG1478
(10 μg/ml), cath-L inhibitor Z-FF-FMK (5 μM) or the H+–ATPase
inhibitor bafilomicin A1 (0.025 μM; all Sigma). Untreated cells and
transfectants treated with DMSO solvent (Sigma) at concentrations
similar to those used in the inhibitor studies were used as negative
controls. Migrated cells were counted in five separate filter areas at
20-fold magnification by bright field microscopy. Mean numbers of
migrated cells per filter were determined and presented in the graphs.
Results represent three independent experiments with each clone being
tested three times with at least three filter sets per experiment.
Incubation with Proteasomal Inhibitors
ProEGFcyt transfectants (8.5 × 104 cells per six-well plate) were
incubated for 24 hours in serum-free medium. Cells were pretreated
with EGF (10 ng/ml; Life Technologies) for 1, 4, 6, and 24 hours
and then treated for 2 hours with proteasome inhibitor MG132 or
lactacystine (both 10 μM; Sigma). Cellular proteins were lysed with
1× SDS gel loading buffer before Western blot analysis.
Transmission Electron Microscopy
ProEGFcyt stable transfectants (8.5 × 104 per six-well plate) were
incubated for 24 hours before fixation for 1 hour at room tempera-
ture in 4% paraformaldehyde, 2.5% glutaraldehyde (both from
EMD, Gibbstown, NJ), 8% sucrose in 0.1M PBS (pH 7.3; both from
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Sigma). Cells were rinsed in PBS three times and incubated for 1 hour
at room temperature in 1% osmium tetroxide (Sigma) in PBS. Cells
were washed five times in double distilled H2O and dehydrated in a
50% to 100% ethanol series. Sections were covered in 100% of Araldite
and incubated overnight at 45°C; images were collected with a CM-10
transmission electron microscope (Philips, Netherlands).
Immunofluorescence and Immunohistochemistry
Immunofluorescent detection of mannose-6-phosphate receptors
(M6PR; clone 2G11; 1:200; Abcam, Cambridge, MA; nonacidic endo-
somes), CD63/LAMP3 (clone NKJ/C3; 1:50; Novocastra, Norwell,
MA; lysosomes), and human procath-L (2D4, 1:100) was performed
as described previously [32]. An Alexa-Fluor-FITC–conjugated second-
ary antimurine antibody was used as secondary antibody (1:400;Molec-
ular Probes, Invitrogen). Human trans-Golgi network (TGN) and
SNAP25 were detected using mAbs against Golgin-97 (1:200, clone
CDF4; Molecular Probes) and SNAP25 (1:400, clone CB 59-4B11;
Cedarlane). Transfectants were plated onto glass slides and cultured to
80% confluence before fixing in 4% paraformaldehyde in PBS. Block-
ing of nonspecific binding sites with 10% normal goat serum in PBS
plus 2% BSA and 0.05% saponin was done for 30 minutes at room
temperature before incubation with primary Ab dilutions in blocking
buffer overnight at 4°C. Sections were washed 3 × 10 minutes in PBS
and incubated with fluorochrome-conjugated secondary antibody
(1:400) for 1 hour at room temperature.Nuclear stainingwas performed
with 0.01 mg/ml Hoechst stain (Sigma). Cells were mounted in fluoro-
guard antifade reagent (Biorad) and viewed with the Axioplan fluores-
cent microscope (Zeiss, Jena, Germany); images were captured and
processed with an AxioCam camera and Axiovision software (Zeiss),
respectively.
For immunohistochemical analysis, 5-μmsections of paraformaldehyde-
fixed and paraffin-embedded FTC mouse thyroid tissues were treated
with 3% hydrogen peroxidase to block endogenous peroxidase activ-
ity. Nonspecific binding were blocked with 3% BSA and 10% goat
normal serum (Sigma). After blocking, the sections were incubated
with ProEGFcyt antiserum in concentration 1:100 overnight at 4°C.
Sections were washed 3 × 10 minutes in PBST buffer and incubated
with secondary antibody goat antirabbit (New England Biolabs) for
1 hour at room temperature in a concentration of 1:300. Staining
was developed using DAB kit (Pierce, Rockford, IL).
Statistics
All experiments were repeated at least three times. For the stable
transfectants, three different clones for each construct were used in all
experiments. For migration assays, the mean value with SE and in-
dependent 2-tailed t test was performed, with P < .05 being consid-
ered significant. For multiple-experiment comparison, ANOVA table
and Tukey’s test were used with P < .05 being regarded significant.
Results
ProEGFcyt Domain Inhibits Motility of Thyroid Cancer Cells
Stable transfectants of the human FTC cell line FTC-133 contain-
ing constructs encoding for previously characterized proEGFcyt con-
structs [27] and the human EGF, juxtamembrane, transmembrane,
and cytoplasmic domain with C-terminal FLAG epitope (EGFctF;
gift from Dr. S. Wiley) [4] were used in this study (Figure 1A).
ProEGFctF was detected as a single band and membrane-associated
protein by Western blot and immunofluorescence using an anti-EGF
and anti-FLAG antibody, respectively (Figure 1, B and C ). Trans-
fectants harboring the empty vector were used as mock control.
Transwell filter assays were used to determine the effect of the differ-
ent proEGFcyt constructs on thyroid tumor cell motility and migra-
tion. In the presence of proEGFctF, we observed a 50% reduction
in motility compared with mock controls (Figure 1D). Treatment
with exogenous EGF enhanced motility, and this increase in motility
was mediated by the EGFR as determined by the inability of EGF to
increase motility in the presence of the specific EGFR inhibitor
AG1478 (Figure 1D) and by the Western blot detection of phos-
phorylated EGFR Tyr 992 residue on EGF treatment (data not
shown). To determine the functional contribution of the proEGF
cytoplasmic domain (proEGFcyt), we used the FTC-133 trans-
fectants that exclusively expressed the full cytoplasmic domain of
human proEGF (proEGFcyt), an engineered proEGFcyt construct
composed of the peptide sequences encoded by exons 22 and 23
of human proEGF (proEGF22.23), and a natural splice form of
proEGFcyt lacking the peptide sequences encoded by exons 23
and 24 (proEGFdel23) [27]. Similar to proEGFctF, the presence
of proEGFcyt caused a 52% and 41% reduction in cell motility in
FTC-133 (Figure 1E ) and transiently transfected UTC-8305
(Figure W1A) and FTC-236 thyroid cancer cells (Figure W2A) com-
pared with proEGFdel23 and mock controls, respectively. Soluble
EGF significantly increased the motility in transfectants expressing
proEGFcyt and proEGF22.23 but not in proEGFdel23 and mock
cells. Thus, proEGFcyt, which is part of the transmembrane region
encoded by EGFctF, was sufficient to act as a negative regulator of
motility in thyroid cancer cells. Moreover, the deletion of exon 23,
as in the proEGFdel23, completely abolished the inhibitory effect on
thyroid cancer cell motility.
ProEGFcyt Domain Is a Novel Negative Regulator of
Elastinolytic Activity
The acquisition of an elastinolytic phenotype by tumor cells is a
unique and important requirement for early tissue invasion and facili-
tates the initial steps of penetration of basal lamina [33,34]. Elastin
migration assays revealed a 50% reduction in elastinolytic invasion in
the presence of EGFctF (Figure 2A). Similarly, elastin matrix pene-
tration was reduced by 50% and 33% with FTC-133–stable trans-
fectants (Figure 2B) and UTC-8305 (Figure W1B) and FTC-236
(Figure W2B) transient transfectants expressing proEGFcyt and
proEGF22.23, respectively, but not with proEGFdel23 and mock
transfectants. Exogenous EGF increased the ability of cells to invade
elastin matrices, and this effect was most pronounced in the presence
of proEGFctF, proEGFcyt, and proEGF22.23 (Figure 2, A and B).
This EGF-induced enhanced elastinolytic migratory activity was de-
pendent on the presence of a functional EGFR and was abolished
when the specific EGFR inhibitor AG1478 was used (Figure 2, A
and B). Thus, we identified human proEGFcyt, and here particularly
the peptide encoded by exon 23, as the component within the
proEGF transmembrane region, which was capable of suppressing
the elastin matrix invasion in thyroid cancer cells. Next, we studied
the relationship between the tissue expression of proEGFcyt and
in vivo thyroid carcinogenesis. We hypothesized that proEGFcyt
levels will diminish in thyroid tissues at advanced stages of thyroid
carcinogenesis. We used our established mouse model of FTC in
which FTC mice develop thyroid cancer starting as early as 5 to
6 months [30]. The anti-proEGFcyt rabbit polyclonal serum recog-
nized both human and mouse proEGFcyt as well as recombinant
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human proEGFcyt in FTC-133–proEGFcyt clones (Figure W3).
Immunodetection with this antiserum was blocked with a GST-
bound human proEGFcyt fusion protein (Figure 2C ). Hyperplastic
thyroid tissues collected at 2.9 months (Figure 2F ) showed already a
significant decrease in immunoreactive proEGFcyt compared with
normal thyroid control tissue (Figure 2D). Tumor tissues from
7.73 and 11.93 months were largely devoid of immunoreactive
proEGFcyt (Figure 2, G and H ), as was normal thyroid tissue in
which the primary antiserum had been replaced with nonimmune
rabbit serum (Figure 2E ). Thus, the down-regulation of proEGF
was an early event during mouse thyroid carcinogenesis.
Decreased Elastinolytic Activity Coincides with Diminished
procath-L Secretion and an Altered Vesicular Phenotype
The lysosomal hydrolase cath-L has potent elastinolytic activity.
We performed Western blot analysis with the well-characterized
mAb 33/1, which detects all three human cath-L forms [31]. Total cell
lysates (CLs) revealed processed cath-L as proform (43 kDa), single-
chain (31 kDa), and processed two-chain cath-L represented by
the heavy chain (24 kDa). All FTC-133 clones (Figure 3A) and
UTC-8305 (Figure W1C ) and FTC-236 (Figure W2C ) transient
transfectants displayed decreased levels of single-chain cath-L com-
pared with FTC-133–proEGFdel23 and mock controls (Figure 3A).
Figure 1. Effect of transmembrane and intracellular motifs of proEGF on cells’ motility and elastinolytic migratory activity. (A) Schematic
drawing of the different human proEGF constructs used in this study. cyt indicates cytoplasmic domain; e22-24, exons 22-24; JR,
juxtamembrane region; TM, transmembrane domain. (B) Stable FTC-133–proEGFctF transfectants expressed the characterized trans-
membrane proEGF construct [4] as detected by antibodies against extracellular EGF and Flag located at the C-terminus of the proEGFctF
construct, respectively. (C) Immunofluorescent detection of Flag antigen confirmed the previously reported association of proEGFctF
with the plasma membrane and the endosomal/Golgi compartment in FTC-133–proEGFctF stable transfectants. (D) We observed
a >50% reduction in cell motility in the presence of proEGFctF and (E) proEGFcyt and proEGF22.23 in FTC-133 transfectants. No
change in cell motility was observed with proEGFdel23 or mock transfectants compared with mock controls (E). When exogenous
EGF (10 ng/ml) was added, a small increase in motility was observed in the presence of proEGFctF (D). However, an almost complete
recovery to mock motility values was observed in proEGFcyt and proEGF22.23 clones (E). Exogenous EGF caused only a slight in-
crease in cell movement with proEGFdel23 and mock transfectants (E). The EGF-induced increase in motility observed with proEGFctF,
proEGFcyt and proEGF22.23 stable transfectants was abolished in the presence of the specific EGFR inhibitor AG1478 (10 μg/ml; D and
E), indicating the involvement of EGF-activated EGFR signaling pathways. AG1478 alone failed to have any effect on cell motility. Results
of three independent motility and migration assay experiments with three filter sets per experiments are shown.
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Figure 2. Effect of proEGFcyt signaling on elastinolytic migration
activity. Elastin migration assays demonstrated a marked reduc-
tion in the ability of human thyroid carcinoma transfectants to
penetrate an elastin matrix in the presence of proEGFctF (A) and
proEGFcyt and proEGF22.23 compared with proEGFdel23 and
mock controls (B). Treatment with exogenous EGF (10 ng/ml) re-
sulted in a significant increase in migration through the elastin
matrix, and this was most pronounced with proEGFcyt and
proEGF22.23 transfectants (B). The EGF-induced increase in elas-
tinolytic migratory activity was mediated by the EGFR and was
abolished in the presence of the specific EGFR inhibitor AG1478
(10 μg/ml). AG1478 itself had no effect (B). Results of three inde-
pendent motility and migration assay experiments with three filter
sets per experiments are shown. For Western blot analysis, we
used a newly generated rabbit antiserum against two pooled pep-
tides that were located within the C-terminus of exon 22 of human
proEGF cytoplasmic domain (C). This antiserum detected human
proEGFcyt in lysates of proEGFcyt stable transfectants, and bind-
ing was inhibited in the presence of excess GST-proEGFcyt human
recombinant protein (C). The antiserum against proEGFcyt cross-
reacted with mouse antigen and detected proEGFcyt in thyroid
tissue sections of normal mice (D). Immunostaining was largely
abolished in thyroid tissues of FTC mice at 2.90 (F), 7.73 (G), and
11.93 months (H) and was absent in thyroid section where the pri-
mary antiserum had been replaced by rabbit nonimmune serum (E).
Figure 3. Modulation of elastinolytic activity by proEGFcyt involves
regulation of procathepsin L secretion. Western blot detection of
the proform (43 kDa), single chain (31 kDa), and the heavy chain of
the fully matured form (24 kDa) of cath-L in the supernatants and total
CLs of FTC-133 (A). Levels for single-chain form of cath-L were signifi-
cantly reduced in the presence of proEGFctF, proEGFcyt, and
proEGF22.23 but not with proEGF22.23 or in mock controls. Treat-
ment with exogenous EGF caused a significant increase in procath-L
secretion particularly in proEGFcyt and proEGF22.23. No increase
in secreted procath-L was detected with proEGFctF (A). Protein con-
centrations in cell lysates and supernatants were determined using
both β-actin as a loading control in Western blots and Bradford assay
for determining the protein concentration in supernatants, respec-
tively. In contrast to clones expressing the membrane-anchored
proEGFctF, FTC-133–proEGFcyt and –proEGF22.23 transfectants
showed increased secretion of procath-L on EGF treatment. Involve-
ment of the EGFR was confirmed by the specific EGFR inhibitor
AG1478, which abolished the EGF-induced and EGFR-mediated in-
crease in procath-L secretion (B). Representative Western blots of
three independent experiments are shown. Elastin migration assays
were used to assess the role of lysosomes and cath-L in the elastino-
lytic migratory phenotype of the transfectants. Cells were treatedwith
exogenous EGF in the presence and absence of the vacuolar H+–
ATPase inhibitor Baf-A1, which prevents acidification of endosomes/
lysosomes and the cath-L inhibitor Z-FF-FMK, respectively (C). The
ability of clones to penetrate elastin matrices was not affected by
Baf-A1 alone or in the presence of exogenous EGF suggesting that
the acidic vesicular compartment did not affect the EGF-mediated
enhanced elastinolytic migratory activity. In mock transfectants that
secrete procath-L, the cath-L inhibitor Z-FF-FMK significantly reduced
the ability to penetrate elastin matrices. Z-FF-FMK had no effect on
the elastinolytic activity of proEGFcyt transfectants as these cells only
secreted very small amounts of detectable procath-L unless stimu-
lated with EGF. Z-FF-FMK abolished the EGF-induced and EGFR-
mediated enhanced elastinolytic migration in both proEGFcyt and
control transfectants (C) indicating that the elastinolytic migratory ac-
tivity measured was the result of cath-L–mediated elastin degradation.
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Treatment with exogenous EGF did not affect the intracellular proces-
sing of cath-L (Figure 3A). With the exception of FTC-133–
proEGFctF, EGF caused a marked up-regulation in secreted procath-
L in the other FTC-133 transfectants and UTC-8305–proEGFcyt
(Figure W1C ) and FTC-236 (Figure W2C ) transient transfectants.
The EGF-induced increase in procath-L secretion was mediated by
the EGFR and was abolished in the presence of the EGFR inhibitor
AG1478 (Figure 3B). Similar results were obtained with UTC-8305
(Figure W1D) and FTC-236 (Figure W2D). To determine a direct in-
volvement of lysosomes and cath-L in the elastinolytic phenotype, we
used the vacuolar H+–ATPase inhibitor bafilomycin A1 (Baf-A1) that
inhibits acidification of endosomes, lysosomes, and phagosomes and
the cath-L inhibitor Z-FF-FMK, respectively. Whereas Baf-A1 had no
effect, Z-FF-FMK abolished the EGF-induced andEGFR-mediated en-
hanced elastinolytic migration in the presence of proEGFcyt and mock
transfectants (Figure 3C ). Similar results were obtained with the FTC-
133–proEGFctF transfectants (data not shown). Immunofluorescent
analysis of proEGFdel23 and mock cells revealed a focal perinuclear
localization of the Golgi and acidic endosome compartments as deter-
mined by Golgin-97 (TGN; Figure 4A), M6PR (Figure 4D), and a
marked granular peripheral cytoplasmic distribution for lysosomes
detected by CD63/LAMP3 (Figure 4G ). By contrast, FTC-133–
proEGFcyt (Figure 4, B, E , andH ) or –proEGF22.23 (data not shown)
and FTC-133–proEGFctF transfectants (Figure 4, C , F, and I ) showed
a circular perinuclear distribution of immunoreactive Golgin-97 (Fig-
ure 4, B and C ), M6PR (Figure 4, E and F ), and CD63/LAMP3
(Figure 4, H and I ). In proEGFdel23 and mock controls, procath-L
showed a more granular staining pattern (Figure 4J ), whereas in the
presence of proEGFcyt (Figure 4K ), proEGF22.23 (not shown), and
EGFctF (Figure 4L), immunoreactive procath-L was frequently local-
ized in the perinuclear space. Transport and maturation of cathepsins
are realized by the endolysosomal vesicular system, and disturbances
in vesicular distribution/trafficking may affect procath-L processing
in the presence of EGFctF and proEGFcyt/proEGF22.23. Marked
accumulation of vesicular structures within the cytoplasm of FTC-
133–proEGFcyt (Figure 4N ) and FTC-133–proEGF22.23 cells, but
not proEGFdel23 and mock controls (Figure 4M ), was apparent by
transmission electron microscopy (Figure 4, M and N ).
ProEGFcyt Is a Novel Regulator of SNAP25 Expression
and Procath-L Secretion
To identify the molecular mechanism by which EGFctF and
proEGFcyt decrease procath-L secretion, we determined the expres-
sion of members of the t-SNARE complex known to be important in
vesicular-membrane fusion. We established EGFctF as a novel tran-
scriptional activator of SNAP25, isoform A (Figure 5A). Again, juxta-
and transmembrane parts of the membrane-anchoring region were
dispensable for this effect. Full-size cytoplasmic domain or the syn-
thetic proEGF22.23 gene products were sufficient in the specific up-
regulation of SNAP25 gene activity in FTC-133 (Figure 5B). Similar
results were obtained on transient transfection of UTC-8305 (Fig-
ure W1E ) and FTC-236 (Figure W2E ). The presence of EGFctF,
proEGFcyt, or proEGF22.23 had no effect on the constitutive expres-
sion of the genes encoding SNAP23 and two other important interact-
ing partners of SNAP25, syntaxin1A and synaptobrevin/VAMP2,
respectively (data not shown). Upon 48 hours of incubation with a
specific siRNA for human SNAP25, we observed an almost complete
and specific down-regulation of SNAP25 mRNA and protein, whereas
a scrambled siRNA control construct had no effect (Figure 5B). Next,
we determined the effect of this SNAP25 knockdown on the produc-
tion, processing, and secretion of (pro)cath-L. FTC-133–proEGFctF
and –proEGFcyt treated with siRNA-SNAP25 did not show differences
in the production and enzymatic processing of procath-L. However, in
the presence of proEGFctF and proEGFcyt, SNAP25-knockdown
caused a marked up-regulation in the secretion of procath-L by 43%
(Figure 5C) and enhanced elastinolytic migration by 46% (Figure 5D).
Thus, we identified the proEGFcyt domain as a negative regulator of
SNAP25-mediated cath-L secretion. This constitutes a novel pathway as-
sociated with elastin matrix invasion of human thyroid carcinoma cells.
ProEGFcyt and EGFR Ligand EGF Regulate SNAP25
Bidirectionally Through Distinct Pathways
We determined the effect of exogenous EGF on SNAP25 mRNA
and protein production in FTC-133–EGFctF and proEGFcyt transfec-
tants of the thyroid carcinoma cell lines studied (FTC-133, FTC-236,
Figure 4. ProEGFcyt and proEGFctF induce altered vesicle and pro-
cathepsin L cellular distribution. Immunofluorescent imaging of
vesicles of the Golgi-endosomal-lysosomal vesicular compartments
in the generally smaller mock cells (A, D, G, J) and the proEGFcyt-
(B, E, H, K) and proEGFctF-stable FTC-133 transfectants (C, F, I,
L). A significant vesicular phenotype was observed in the presence
of proEGFcyt and proEGFctF with altered distribution of TGN (Golgin-
97; A–C), acidic endosomes (M6PR; D–F), and lysosomal com-
partment (CD63/LAMP3; G–I). The proEGFctF, proEGFcyt, and
proEGF22.23 clones showed similar results and differed markedly
from mock controls that were similar to proEGFdel23 clones (three
clones per construct). Distribution of procath-L (J, K, L) in the pres-
ence of proEGFcyt (K) and proEGFctF (L) was similar to Golgin-97 (B)
and M6PR (E) immunostaining. Mock controls showed a vesicular
distribution of procath-L (J) similar to that of lysosomes (G). Repre-
sentative transmission electron microscopy (TEM) analysis revealed
multiple vesicular structures in the cytosol of FTC-133–proEGFcyt
transfectants (M). Mock controls did not display this extensive vesic-
ular phenotype (N).Mito indicates mitochondria; V , vesicles. Original
magnifications: A–I, ×620; J–L, ×400; M and N, ×5500.
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and UTC-8305). The decrease in SNAP25 protein observed with
EGF treatment was not the result of an EGF-induced down-regulation
of SNAP25 gene activity as determined by RT-PCR (data not shown).
Short-term incubations of EGFctF and proEGFcyt clones with EGF
for up to 1 hour had no effect on the intracellular SNAP25 protein
levels but activated EGFR as determined by the detection of EGFR
phosphorylation at residue Tyr 992 inWestern blots (data not shown).
Treatment with EGF for 4 and 6 hours resulted in a significant down-
regulation of SNAP25 protein as shown for proEGFcyt clones (Fig-
ure 6, A and B). This EGF-induced down-regulation of SNAP25
was dependent on the activation of EGFR and was abolished in the
presence of AG1478 (Figure 6A). When proEGFcyt transfectants of
FTC-133 and UTC-8305 were treated with the two proteasome in-
hibitors, MG132 or lactacystine, the EGF-induced down-regulation
of SNAP25 was abolished indicating that EGF-induced EGFR activa-
tion was involved in the proteasomal degradation of SNAP25 as early
as 4 hours after EGF exposure in FTC-133–proEGFctF/–proEGFcyt
(Figure 6B) and UTC-8305–proEGFcyt (Figure W1E) and FTC-236
(Figure W2E) transient transfectants. Thus, we identified proEGFcyt
and the extracellular EGFR ligand EGF to act as functional antagonists
Figure 5. ProEGFctF regulates procathepsin L availability through
transcriptional regulation of SNAP25. Using specific primers to
human SNAP25A+B, RT-PCR analysis revealed a selective up-
regulation of SNAP25A mRNA expression in the presence of
proEGFctF (A). Western blot revealed increased SNAP25 protein
production exclusively in proEGFctF transfectants but not in mock
controls (A). Similarly, proEGFcyt and proEGF22.23 caused an
up-regulation of SNAP25 mRNA and protein (B). A specific siRNA-
SNAP25 construct was used to knockdown SNAP25 mRNA expres-
sion and protein production (B) in FTC-133–proEGFcyt clones. A
nonsilencing, randomized sequence not matching known human
genes was used as a control in the siRNA experiments (B). Repre-
sentative RT-PCR and Western blot analysis of three independent
experiments are shown. FTC-133–proEGFcyt and FTC-133–
proEGF22.23 transfectants treated with siRNA-SNAP25 or siRNA-
control were probed for secreted procath-L using the mAb 2D4
specific for the detection of procath-L. SNAP25 knockdown caused
an approximately 43% up-regulation of secreted procath-L when
compared to treatment with siRNA-control as shown in a represen-
tative Western blot and densitometric analysis (C). This corre-
sponded to a 46% increase in the number of siSNAP15-treated
FTC-133–proEGFcyt clones migrating through the elastin matrix
(D). Results of three independent experiments with three filter sets
per experiments are shown.
Figure 6. Opposing effects of EGF and proEGFcyt in the presence
of SNAP25. Representative Western blots showing SNAP25 pro-
tein in FTC-133–proEGFcyt transfectants with and without EGF
treatment for 1, 6, and 24 hours in the presence and absence of
the specific EGFR inhibitor AG1478 (A). A decrease in SNAP25 im-
munoreactive protein after 6 hours of incubation with exogenous
EGF was observed (A). The EGF-induced decrease in SNAP25
protein production was diminished in the presence of the EGFR
inhibitor AG1478 (A). Similar results were obtained with UTC-8305-
proEGFcyt and FTC-236-proEGFcyt (Figures W1E and W2E ). Treat-
ment with the proteasomal inhibitor MG132 abolished the EGF-
induced down-regulation of SNAP25 protein in FTC-133–proEGFctF
and –proEGFcyt clones (B). Beta-actin was used to confirm equal
protein loading and representative Western blots of three indepen-
dent experiments are shown. (C) Schematic illustration of the role
of human proEGF (membrane-anchored and cytosolic) and the extra-
cellular EGFR ligand domain, EGF, in affecting elastinolytic inva-
siveness by human thyroid carcinoma cells. We identified a novel
multifaceted role of proEGF functional domains in the regulation
of exocytosis and procath-L secretion by human thyroid tumor cells.
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by regulating the intracellular level of SNAP25. This affected the secre-
tion of procath-L and the elastinolytic invasion potential of human thy-
roid carcinoma cells (Figure 6C ).
Discussion
The EGF-EGFR ligand-receptor system has important functions
in normal thyroid physiology and tumor cell progression/invasiveness
and affects the clinical outcome in patients with thyroid carcinoma
[35,36]. Using our mouse model of FTC carcinogenesis and a new
antiserum specific for proEGFcyt, we detected an inverse relationship
between the tissue expression of immunoreactive proEGFcyt, thyroid
tumor stage, and enhanced tissue invasion and metastasis. Here, we
have investigated the role of the transmembrane region of human
proEGF and identified the proEGF cytoplasmic domain as a novel
negative regulator of motility and elastinolytic activity in thyroid carci-
noma cells. We found that the inhibition of elastinolytic activity and
reduced invasion of elastin matrices in the presence of proEGFcyt was
caused by the specific transcriptional up-regulation of the t-SNARE
component SNAP25 resulting in the reduced secretion of the potent
elastinolytic lysosomal hydrolase procath-L. Treatment with EGF an-
tagonized this inhibitory function encoded by proEGFcyt, and both
components of human proEGF engaged in different signaling path-
ways to mediate their opposing cellular actions. The suppressive action
of proEGFcyt on thyroid carcinoma cell motility and elastinolytic ac-
tivity seemed to be independent of EGFR activation, and the peptide
sequence encoded by exon 23 was essential for the proEGFcyt-induced
cellular actions. We had previously demonstrated a hyperacetylated
microtubular phenotype and increased production of the microtubule-
associated proteins MAP1b and MAP2c in thyroid carcinoma trans-
fectants expressing proEGFcyt and proEGF22.23 but not a construct
with a deletion of exon 23 (proEGFdel23) [27]. The level of tubulin
acetylation has been shown to inversely correlate with cell motility
[37]. Treatment with exogenous EGF had no effect on the acetylation
status of α-tubulin in the proEGFcyt clones tested (T.K., unpublished
observations) indicating that this posttranslational microtubular
modification was not a likely point of convergence between the en-
hancing action of EGF and the suppressive effects of proEGFcyt
on motility. However, these microtubular changes may have con-
tributed to the unique vesicular distribution detected in proEGFcyt
and proEGF22.23 transfectants. In the presence of proEGFctF and
proEGFcyt/proEGF22.23, we observed more extensive intracellular
processing of the procath-L compared with proEGFdel23 and mock
control cells. This likely reflected prolonged exposure of procath-L
to the acidic conditions found in late endosomes and lysosomes
[38,39]. In the Golgi apparatus, M6P is added specifically to carbo-
hydrates of newly synthesized lysosomal enzymes, and this M6P is
used by M6PR located at the inner membrane of the TGN to escort
procathepsins from the TGN to the prelysosomal/late endosome acidi-
fied compartment [40]. Catalyzed by the acidic pH, the prelysosomal
cathepsins dissociate from M6PRs, and final processing of cathepsins
takes place in the lysosomes [41]. The acquisition of an elastinolytic
phenotype is an important step in the ability of tumor cells to pene-
trate the basal lamina and initiate the invasion of surrounding tissues
[33]. Cath-L has strong elastinolytic activity and is up-regulated in
tumor tissues [42,43], including thyroid carcinoma [32,44]. Cath-B,
another elastinolytic cathepsin, was not secreted by the thyroid cancer
cells studied and, thus, was unlikely to contribute to elastin matrix
degradation. Treatment with the cath-L/-B inhibitor Z-FF-FMK
[45] abolished the ability of thyroid carcinoma transfectants to pene-
trate elastin matrices indicating that this function was dependent on
the secretion of procath-L and cath-L–mediated degradation of elastin.
Interestingly, we observed procath-L, but no maturation products
thereof, to be the sole cath-L form secreted. Neutralization of the
acidic vesicular compartments by the vacuolar H+–ATPase inhibitor
Baf-A1 [46] did not impair the ability of thyroid cancer cells to pene-
trate elastin matrices. Secretion of procath-L has been observed in nor-
mal cells [47,48] and in cells undergoing growth stimulation and
malignant transformation [49]. Although procath-L does not seem
to have direct elastinolytic activity, extracellular processing of pro-
cath-L occurs at the plasma membrane surface at low pH and in the
presence of negatively charged surface molecules, e.g., chondroitins or
keratan sulfates [50,51]. This is particularly true for tumor cells that
acidify their surrounding extracellular milieu [52]. Thus, extracellular
(but not intracellular) pH-dependent processing of procath-L likely
contributed to the enhanced elastinolytic migratory activity observed
in the human follicular and anaplastic thyroid carcinoma transfectants.
ProEGFcyt affected the secretion of procath-L and elastinolytic
tumor cell invasiveness by a unique and selective transcriptional up-
regulation of SNAP25A in all three thyroid carcinoma cells studied.
SNAP25 has previously been implicated as a genetic susceptibility
factor for attention-deficient/hyperactivity disorder [53] and dysregu-
lation of insulin secretion from pancreatic β-cells in diabetes [54,55].
The plasma membrane-bound soluble N -ethylmaleimide–sensitive
factor attachment protein receptor (SNARE) proteins syntaxin1A
and synaptosome-associated protein of 25 kDa (SNAP25) and the ve-
sicular SNARE partner vesicle-associated membrane protein (VAMP)
are essential components for Ca2+-dependent regulated exocytosis
[56,57]. The amino-terminal SNARE motif of SNAP25 engages
in a high-affinity heterodimer plasma membrane complex with
syntaxin1A and, on interaction with the vesicular synaptobrevin/VAMP,
generates the core trimer formation essential for vesicular mem-
brane fusion [58]. Neither proEGFctF nor proEGFcyt affected the
expression of ubiquitously present SNAP23, another member of
the SNAP25 protein family, suggesting an as yet unknown mecha-
nism by which the proEGF transmembrane region, and here par-
ticularly proEGFcyt, can affect SNAP25 gene activity resulting in
changes in exocytosis.
Our data revealed a unique domain-specific involvement of human
proEGF in the exocytosis of procath-L–containing vesicles in thyroid
cancer cells. By affecting intracellular SNAP25 protein levels in op-
posite ways, the soluble extracellular EGFR ligand EGF and the
intracellular proEGFcyt were identified as novel regulatory factors
able to modulate procath-L secretion and elastin invasion in thyroid
tumor cells. It has previously been shown that the specific stoichiome-
try of the anchoring proteins syntaxin1A and SNAP25 is a decisive
determinant for efficient vesicle fusion with the plasma membrane
and has a direct impact on the exocytotic efficacy and associated
biologic functions. Changes in protein levels of either SNAP25 or
syntaxin1A were shown to decrease glucose-stimulated insulin release
in normal rat islets [54,59], but the regulatory elements of these pro-
cesses remain largely unknown.
In conclusion, the transcriptional up-regulation of SNAP25 gene
activity by proEGFctF and proEGFcyt and the proteasomal degrada-
tion of SNAP25 protein by EGF-induced EGFR activation provide
a novel system for tumor cell invasiveness. This may have implica-
tions beyond human thyroid carcinoma and reflect a molecular
mechanism effective in physiological processes and in other proEGF-
producing cancers.
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Figure W1. (A) Reduced motility of UTC-8305 transiently transfected with the human proEGFcyt construct. Exogenous EGF antagonized
this motility-suppressive effect of proEGFcyt. (B) Transient expression of proEGFcyt impaired the ability of UTC-8305 to migrate through
the elastin matrix, and this inhibitory effect was counteracted by soluble EGF. (C) UTC-8305 displayed significantly decreased secretion
of procath-L in the presence of proEGFcyt. Incubation with soluble EGF reversed this phenotype and resulted in markedly enhanced
secretion of procath-L. Epidermal growth factor treatment had no effect on untransfected or mock-treated UTC-8305. (D) The increase in
the secretion of procath-L by soluble EGF was mediated by the EGFR and was inhibited in the presence of the specific EGFR inhibitor
AG1478. No change in procath-L secretion was observed in mock controls on treatment with soluble EGF, AG1478, or DMSO solvent
(data not shown). (E) In the presence of transiently expressed proEGFcyt, UTC-8305 displayed an up-regulation of SNAP25 mRNA (not
shown) and SNAP25 protein (25 kDa). Treatment with exogenous EGF resulted in a significant decrease in SNAP25 production. Equal
protein loading was confirmed with β-actin. All Western blots are representative examples of three independent experiments.
Figure W2. (A) Transient transfection of FTC-236 cells using proEGFcyt construct resulted in a decrease in tumor cell motility. Treatment
with soluble EGF antagonized the inhibitory action of proEGFcyt and significantly increased motility of FTC-236. (B) Similar inhibitory
action of proEGFcyt was observed during cell migration through an elastin matrix and exogenous EGF enhanced elastinolytic migratory
activity. (C) ProEGFcyt inhibited secretion of procath-L in FTC-236, and this effect was counteracted by soluble EGF. (D) The increase in
the secretion of procath-L by soluble EGF was mediated by the EGFR and inhibited in the presence of AG1478. (E) In the presence of
proEGFcyt, both mRNA and protein level of SNAP 25 were up-regulated in FTC-236 and treatment with soluble EGF decreases protein
level of SNAP25.
Figure W3. (A) Western blot detection of proEGFcyt using the rabbit polyclonal antiserum against human proEGFcyt. ProEGFcyt protein
content was monitored at 4, 8, 24, and 48 hours of culture. Higher protein concentrations of proEGFcyt detected at 24 and 48 hours
coincided with higher numbers of cells per well at these time points as verified by β-actin and (B) corresponding densitometry repre-
senting three independent experiments. (C) Detection of proEGFcyt using the anti-Xpress tag antibody. (D) Again, densitometry of six
independent Western blot analyses failed to show significant difference in protein content for the different proEGF mutant proteins at
24 hours in FTC-133 transfectants. β-Actin was used to determine the relative amount of proteins for densitometric measurements. In
conclusion, different stable transfectants contained similar amounts of proEGF recombinant proteins over time. The same protein ex-
tracts had been used for the detection of SNAP25 and procath-L.
